Raabta Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 4.03 M
- Revenue Growth 4810.10%
- Profit Growth -9.61%
- Ebitda 38.62%
- Net Worth -206.29%
- Total Assets 82.33%
About Raabta Pharma
Raabta Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 August 2018 (Six years and five months 18 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.03 M.
Gudelli Patak and Pusati Reddy serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24236TG2018PTC126275
-
Company No.
126275
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Aug 2018
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Raabta Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gudelli Patak
|
Director | 23-Aug-2018 | Current |
|
Pusati Reddy
|
Director | 23-Aug-2018 | Current |
Financial Performance of Raabta Pharma.
Raabta Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 4810.1% increase. The company also saw a slight decrease in profitability, with a 9.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 206.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raabta Pharma?
In 2021, Raabta Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Cns Labs Private LimitedGudelli Patak is a mutual person
Charges (Loans)
₹4.03 M
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Aug 2021 | City Union Bank Limited | ₹4.03 M | Open |
How Many Employees Work at Raabta Pharma?
Unlock and access historical data on people associated with Raabta Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raabta Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raabta Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
